Company Deep Dive
Business segments breakdown, earnings transcript analysis, management credibility scoring, competitive landscape, and scenario modelling.
AKTS
Strong SellAktis Oncology, Inc. · Healthcare · United States · $1.4B · Avg Vol: $7M/d
COMPANY DESCRIPTION
Aktis Oncology, Inc. is a biotechnology company developing novel radiopharmaceutical therapeutics for the treatment of solid tumors. It focuses on creating targeted alpha-emitting radiopharmaceuticals with improved tumor penetration and systemic distribution, aiming for superior efficacy in oncology. The company is a clinical-stage biotech innovator in the emerging radiopharmaceutical space, seeking to revolutionize cancer treatment through precision medicine.
FINANCIAL SUMMARY (USD)
| Year | 2022 | 2023 | 2024 | 2025 | CAGR | TTM | 2026E | 2027E | Fwd CAGR |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 0 | 0 | 1.5M | 6.5M | 336.9% | 10.1M | 10.0M | 9.5M | 21.2% |
| EPS | -0.51 | -0.82 | -1.26 | -1.21 | — | -1.32 | -1.65 | -2.08 | — |
| Shares | 52.5M | 52.5M | 52.5M | 52.5M | 0.0% | 53.7M | — | — | — |
| Debt | 1.8M | 13.4M | 12.0M | 11.5M | 86.7% | 11.2M | — | — | — |
| Equity | -19.2M | -46.3M | -87.8M | -146.1M | — | — | — | — | — |
| Op CF | -18.1M | -30.0M | 14.8M | -64.1M | — | -75.3M | — | — | — |
| Inv CF | -2.3M | -68.8M | -190.4M | 66.0M | — | — | — | — | — |
| Fin CF | 120.0M | 0 | 183.3M | -1.2M | — | — | — | — | — |
SCORE BREAKDOWN
FUNDAMENTALS
SECTOR PEERS
Closest peers in Healthcare, ranked by industry match, size, and score similarity. Cross-listings of AKTS are excluded.
| Ticker | Company | Mkt Cap | StockRank | Signal |
|---|---|---|---|---|
| AKTS | Aktis Oncology, Inc.(you) | $1.4B | 12 | Strong Sell |
| AVLN | Avalyn Pharma Inc. | $1.5B | 11 | Strong Sell |
| TYRA | Tyra Biosciences, Inc. | $1.5B | 10 | Strong Sell |
| MAZE | Maze Therapeutics, Inc. | $1.5B | 9 | Strong Sell |
| LTGO | Latigo Biotherapeutics, Inc. | $1.5B | 8 | Strong Sell |
| GLUE | Monte Rosa Therapeutics, Inc. | $1.1B | 12 | Strong Sell |
| SPTX | Seaport Therapeutics, Inc. | $1.3B | 9 | Strong Sell |
| RXRX | Recursion Pharmaceuticals, Inc. | $1.8B | 13 | Strong Sell |
| KARD | Kardigan, Inc. | $1.9B | 11 | Strong Sell |
| CRVS | Corvus Pharmaceuticals, Inc. | $1.2B | 10 | Strong Sell |
Peer medians: ROE -25.8% · P/E 29.5x · Gross margin 58.8%